For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.
Selpercatinib, LOXO-292, LY3527723
- Mulligan LM. Nat Rev Cancer. 2014;14:173-186.
- Lipson D, et al. Nat Med. 2012;18(3):382-384.
- Takeuchi K, et al. Nat Med. 2012;18(3):378-381.
- Bounacer A, et al. Oncogene. 1997;15(11):1263-1273.
- Prescott JD, Zeiger MA. Cancer. 2015;121(13):2137-2146.
- Ballerini P, et al. Leukemia. 2012;26(11):2384-2389.
- Bossi D, et al. Mol Oncol. 2014;8(2):221-231.
- Stransky N, et al. Nat Commun. 2014;5:4846.
- Hofstra RM, et al. Nature. 1994;367(6461):375-376.
- Agrawal N, et al. J Clin Endocrinol Metab. 2013;98(2):E364-E369.
- Taccaliti A, et al. Curr Genomics. 2011;12(8):618-625.
- Subbiah V, et al. Ann Oncol. 2018;29:1869-1876.
- Drilon A, et al. LIBRETTO-001: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. Presented at: ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.